Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201109094 Principal Investigator: Linehan, David
Title: Perioperative Treatment with Zoledronic Acid in Patients with Resectable Pancreas Cancer
Phase: II Disease Site: Pancreas
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
You may be asked to participate in this study because you have pancreas cancer. The overall
purpose of this research is to evaluate the safety and toxicity (side effects) of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer. Zoledronic acid is a chemical that was originally designed to prevent the loss of calcium from your bones; however, zoledronic acid has been found to have other effects, including what appear to be anti-cancer
effects. The way which zoledronic acid fights cancer is unknown. We believe that zoledronic acid works by helping the body’s immune system fight the cancer. We are not sure, though, whether zoledronic acid will help fight your type of cancer.
Zoledronic acid is an FDA-approved medication currently used by to treat metastases (cancer
spread to other parts of the body) associated with solid tumors that have traveled to the bone. Currently there are studies evaluating if zoledronic acid can prevent cancer from spreading and help patients to live longer when used with surgery to remove the cancer. Currently it is not known whether zoledronic acid will have this effect in pancreas cancer. For the purposes of this study, zoledronic acid is considered investigational (not approved by the FDA for this indication).
 
More Information:
ClinicalTrials.gov entry
Internal Protocol Documents (requires Siteman administrative database password)